

**(19) World Intellectual Property  
Organization**  
International Bureau

**(43) International Publication Date**  
**13 March 2014 (13.03.2014)**



**(10) International Publication Number**  
**WO 2014/039013 A8**

**(51) International Patent Classification:**

|                                    |                                    |
|------------------------------------|------------------------------------|
| <b><i>C07K 14/00</i></b> (2006.01) | <b><i>A61K 38/16</i></b> (2006.01) |
| <b><i>C07K 7/00</i></b> (2006.01)  | <b><i>A61L 12/14</i></b> (2006.01) |
| <b><i>A61K 38/04</i></b> (2006.01) | <b><i>A61P 31/04</i></b> (2006.01) |

**(21) International Application Number:**

PCT/SG2013/000390

**(22) International Filing Date:**

9 September 2013 (09.09.2013)

**(25) Filing Language:**

English

**(26) Publication Language:**

English

**(30) Priority Data:**

201206715-3 7 September 2012 (07.09.2012) SG

**(71) Applicants: AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). **SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block, Singapore 168753 (SG).

(72) **Inventors:** **BEUERMAN, Roger**; Singapore Eye Research Institute, 11 Third Hospital Avenue, SNEC building Level 5, Singapore 168751 (SG). **LIU, Shouping**; Singapore Eye Research Institute, 11 Third Hospital Avenue, SNEC building Level 5, Singapore 168751 (SG). **RAJAMANI, Lakshminarayanan**; Singapore Eye Research Institute, 11

Third Hospital Avenue, SNEC building Level 5, Singapore 168751 (SG). **VERMA, Chandra**; Bioinformatics Institute, 30 Biopolis Street, #07-01 Matrix, Singapore 138671 (SG). **LI, Jianguo**; Singapore Eye Research Institute, 11 Third Hospital Avenue, SNEC building Level 5, Singapore 168751 (SG).

(74) **Agent: CHUNG, Jing Yeng;** Marks & Clerk Singapore LLP, Tanjong Pagar, P O Box 636, Singapore 910816 (SG).

**(81) Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

*[Continued on next page]*

**(54) Title:** TETRABRANCHED PEPTIDES AND ANALOGUES AS A NEW CLASS OF ANTIMICROBIALS AND THEIR PREPARATION THEREOF




Figure 1

**(57) Abstract:** The invention relates to an isolated peptide tetramer comprising the formula  $[(RGRKWRR)2K]2KK$  and its derivatives thereof. The derivatives may comprise at least one amino acid substitution, at least one amino acid deletion, a rearrangement of the peptide monomer and/or at least one non-proteogenic amino acid modification in at least one peptide monomer. The isolated peptide tetramer and derivatives thereof have antimicrobial (antibacterial, antifungal and/or anti-protozoan) properties.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, KM, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*

**(48) Date of publication of this corrected version:**

15 May 2014

**(15) Information about Correction:**

see Notice of 15 May 2014